Status:
COMPLETED
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Dementia
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.
Eligibility Criteria
Inclusion
- Subject is a nonsmoker
- Subject is in generally good health
- Subject has normal (or corrected to normal) vision and hearing
- Subject is right-handed
Exclusion
- Subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret
- Subject has a history of stroke, seizures, or major neurological disorders
- Subject has a history of cancer
- Subject has permanent cosmetic or metallic implants that would interfere with measurements
- Subject has a history of sleep apnea
- Subject has a history of head injury/trauma
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00887601
Start Date
August 1 2007
End Date
May 1 2008
Last Update
July 30 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.